![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PFIZER JAPAN OBTAINS APPROVAL FOR GENOTROPIN TREATMENT FOR ADULT GROWTH HORMONE DEFICIENCY
PFIZER JAPAN OBTAINS APPROVAL FOR GENOTROPIN TREATMENT FOR ADULT GROWTH HORMONE DEFICIENCY
August 8, 2006
Pfizer Japan Inc. has received the approval of Genotropin for Adult Growth Hormone Deficiency patients (aGHD). Genotropin is considered the top drug in this market and has been certified in 66 countries worldwide. JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=12991)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct